Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00399698 · ClinicalTrials.gov registry record · Phase 3
Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.
A Phase 3 study, sponsored by Ohio State University.
- Completed
- Registry status
- Phase 3
- Development phase
- 30
- Enrollment target
NCT00399698 is a Phase 3 study that has completed, run by Ohio State University. The registered enrollment target is 30 participants.
The verdict
NCT00399698, a Phase 3 study, has completed, sponsored by Ohio State University.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 30 participants
- Enrollment target
Study Summary
This study was developed in order to assess the effects of risperidone (Risperdal) as compared with placebo on cognitive-motor performance (attention, memory, and hand steadiness) and body movements. We propose to study the effects of risperidone on cognitive-motor performance in children already medicated for severe conduct problems. We would also like to look at safety by assessing these children for dyskinetic movements. We already have a sizable cohort of children maintained on risperidone. Our hypotheses are as follows: 1. Risperidone will have no adverse effects on cognitive-motor performance in children who have received maintenance therapy for 4 to 20 months. 2. Children tested during placebo will show no more dyskinetic movements than during risperidone treatment (i.e., there will be no unmasking of tardive dyskinesia).
Interventions
- DRUG Risperdal
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 30 participants |
| Start Date | 1999-05 |
| Est. Completion | 2005-06 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00399698
The ClinicalTrials.gov registry entry for NCT00399698 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 30 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ohio State University, which has 552 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 1 intervention - of which Risperdal is the first listed.
NCT00399698 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00399698 about?
NCT00399698 is a clinical study titled "Study to Determine Whether There Are Any Cognitive or Motor Effects From Taking the Medicine Risperidone.". This study was developed in order to assess the effects of risperidone (Risperdal) as compared with placebo on cognitive-motor performance (attention, memory, and hand steadiness) and body movements. We propose to study the effects of risperidone on cognitive-motor performance in children already m...
What is the current status of trial NCT00399698?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 30 participants. The study started on 1999-05. Estimated completion is 2005-06.
What interventions are being tested in trial NCT00399698?
The interventions under investigation include: Risperdal (DRUG).
Who is sponsoring clinical trial NCT00399698?
This trial is sponsored by Ohio State University, which has 552 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.